BioPharma Credit

BPCRUnknown Sector
0.8845USD
0.06%
Market Cap
998.89M
Volume
44.93k
5% of avg
P/E Ratio
EPS (TTM)
N/A
Beta
N/A
Day Range
0.8800p - 0.8858p
52 Week Range
0.8000p0.8845p0.9400p
0.8845p

Upcoming Events

31 May 2025
Evolus Loan Facility Maturity
June 2025
Tranche B of $50 million to be drawn, subject to conditions
High Impact Event
9 June 2025
Annual General Meeting
Late 2026
Evolus Additional Tranches Availability Deadline
High Impact Event
BPCR
NEUTRAL

BioPharma Credit PLC Announces Director/PDMR Shareholding

The company has announced a change in shareholding by a person closely associated with a director.

BPCR
NEUTRAL

BioPharma Credit PLC Announces Annual General Meeting

The life sciences investment company announces details of its upcoming Annual General Meeting.

BPCR
NEUTRAL

BioPharma Credit PLC Provides Updates on Investments

The investment trust provides updates on partial prepayment from BioCryst Pharmaceuticals and additional investment commitment to Evolus, Inc.

BPCR
NEUTRAL

BioPharma Credit Announces Change in Major Shareholding

The asset manager Adage Capital Management has reduced its stake in the investment trust BioPharma Credit PLC.

BPCR
NEUTRAL

BioPharma Credit Receives $8.25M Settlement from Biogen

The life sciences debt investor has received a settlement payment from Biogen, resolving a dispute over a loan agreement.

BPCR
NEUTRAL

BioPharma Credit PLC Announces Director Dealings

The major biopharmaceutical investment company has announced changes to its major shareholdings.

BPCR
NEUTRAL

BioPharma Credit Appoints Investec as Joint Corporate Broker

The life sciences debt investor has appointed Investec Bank plc as a joint corporate broker alongside JPMorgan Cazenove.

BPCR
NEUTRAL

BioPharma Credit PLC Announces Director Dealings

The major shareholder Adage Capital Management L.P. has reduced its stake in the biopharmaceutical investment company.

BPCR
NEUTRAL

BioPharma Credit PLC Announces Director Shareholding Transaction

The retailer has announced a director's personal shareholding transaction, with no further details provided.